Hims & Hers Health (NYSE:HIMS) shares were on a massive run, but that momentum hit a wall recently. Since its peak on ...

Roller-coaster healthcare stock Hims & Hers Health (NYSE: HIMS), whose stock got devastated last week by worries that it ...

Hims & Hers (NYSE: HIMS) is taking investors on a roller-coaster ride in 2025. Where to invest $1,000 right now? Our analyst ...

Four-star-rated analyst Daniel Grosslight at Citi reiterated his Sell rating on Hims & Hers Health (HIMS) stock yesterday, ...

Hims & Hers Health ( HIMS -12.79%) stock took a tumble Thursday morning, falling 9.2% through 11:40 a.m. ET on some ...

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.

Hims & Hers is shutting down Apostrophe, the skincare company it acquired in 2021, after a tumultuous month for the public ...

Hims & Hers (NYSE: HIMS) stock is down 50% from its peak earlier this year, but the drop in shares hasn't been driven by deteriorating operations. In fact, the company is growing as fast as ever.

The rapid rise of GLP-1 weight-loss drugs has come with a raucous side show—a wave of copycat drugs unbound by drug patents.

Hims & Hers saw a massive YTD surge, but FDA news led to a pullback. Find out why HIMS stock is still undervalued and why ...

Hims & Hers Health's revenue grew 69% YoY, boosting its outlook. See why HIMS stock’s growth potential and high implied ...

Hims & Hers Health stock drops over 20% after the FDA removes semaglutide from the shortage list. Novo Nordisk launches a ...